
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 23 years ago
Mass Customization: The Next Generation of Pharmacy Management





